Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Cozaar Will Get Stroke Risk Reduction Claim – FDA’s Temple

Executive Summary

Merck Cozaar data from the LIFE study support a risk reduction claim for strokes rather than a broader new indication, FDA Office of Medical Policy Director Robert Temple, MD, said

You may also be interested in...



King & Spalding’s healthcare practice expands

King & Spalding announced the addition of two senior advisors to its healthcare practice July 24. Beverly Lorell, most recently VP and Chief Medical and Technology Officer at Guidant, will specialize in areas such as clinical trial design, recalls, and pre-marketing materials. Lorell served on FDA's Cardiovascular and Renal Drugs Advisory Committee (1"The Pink Sheet" Jan. 13, 2003, p. 18). Attorney Kay Scanlan, a former consultant for biotech, drug and medical device industries, will specialize in reimbursement. Scanlan previously served in the Office of General Counsel for CMS and as director-reimbursement strategy for Biogen Idec...

King & Spalding’s healthcare practice expands

King & Spalding announced the addition of two senior advisors to its healthcare practice July 24. Beverly Lorell, most recently VP and Chief Medical and Technology Officer at Guidant, will specialize in areas such as clinical trial design, recalls, and pre-marketing materials. Lorell served on FDA's Cardiovascular and Renal Drugs Advisory Committee (1"The Pink Sheet" Jan. 13, 2003, p. 18). Attorney Kay Scanlan, a former consultant for biotech, drug and medical device industries, will specialize in reimbursement. Scanlan previously served in the Office of General Counsel for CMS and as director-reimbursement strategy for Biogen Idec...

Meta-Analysis In Lancet Projects End of Beta-Blockers For Hypertension

Beta-blockers should not remain the first-line therapy for high blood pressure, researchers of a study published in the Oct. 18 Lancet said

Related Content

UsernamePublicRestriction

Register

PS041096

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel